Medscape4d
Intravenous to Subcutaneous Infliximab Switch Shows Promise in IBD Management
Switching from IV to subcutaneous infliximab maintenance therapy is associated with high treatment persistence and a stable ...
The Pharma Letter2d
Celltrion unveils new post-hoc analyses of LIBERTY studies
South Korean biosimilars developer Celltrion late yesterday announced new post-hoc analyses of its pivotal LIBERTY studies ...
pharmaphorum3d
The rise and market race of anti-IL23p19 therapies in IBD: How ECCO 2025 readouts will shape the anti-interleukin landscape
The treatment landscape of Inflammatory Bowel Disease (IBD) has undergone a significant transformation over the past two ...
Le Lézard3d
Survey Reveals 60% of District Leaders Are Dissatisfied with the Effectiveness of Adolescent Literacy Programs
Many school district leaders1 are committed to integrating the science of reading principles into instruction. However, 60% are dissatisfied with the effectiveness of their current adolescent literacy ...
Le Lézard3d
Applied Policy Welcomes Linda Rouse O'Neill as VP of Health Policy
Applied Policy is pleased to announce the appointment of Linda Rouse O'Neill as Vice President of Health Policy specializing in medical device coverage, coding and reimbursement. O'Neill brings ...
Drug Store News4d
Generic drug suppliers weigh in on predictable, unpredictable category impact
Biosimilars have also made inroads among generic suppliers. But development is lengthy and expensive. McKinsey estimates that it costs $100 to $300 million to develop a biosimilar and that it takes ...
gut.bmj6d
Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD
We investigated whether patients with inflammatory bowel disease treated with infliximab have attenuated serological responses to a single dose of a SARS-CoV-2 vaccine. Design Antibody responses and ...